523 related articles for article (PubMed ID: 30847728)
1. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Zhang B; Long EF
Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
[No Abstract] [Full Text] [Related]
4. Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.
Wan X; Zhang Y; Ma J; Tan C; Zeng X; Peng L
Breast; 2019 Feb; 43():1-6. PubMed ID: 30342258
[TBL] [Abstract][Full Text] [Related]
5. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
6. First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Janni W; Alba E; Bachelot T; Diab S; Gil-Gil M; Beck TJ; Ryvo L; Lopez R; Tsai M; Esteva FJ; Auñón PZ; Kral Z; Ward P; Richards P; Pluard TJ; Sutradhar S; Miller M; Campone M
Breast Cancer Res Treat; 2018 Jun; 169(3):469-479. PubMed ID: 29404806
[TBL] [Abstract][Full Text] [Related]
7. First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.
Huang X; Lin S; Rao X; Zeng D; Wang H; Weng X; Huang P
Clin Breast Cancer; 2021 Aug; 21(4):e479-e488. PubMed ID: 33676870
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Matter-Walstra K; Ruhstaller T; Klingbiel D; Schwenkglenks M; Dedes KJ
Breast Cancer Res Treat; 2016 Jul; 158(1):51-57. PubMed ID: 27277747
[TBL] [Abstract][Full Text] [Related]
9. Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
Biskupiak J; Oderda G; Brixner D; Tang D; Zacker C; Dalal AA
J Manag Care Spec Pharm; 2019 Aug; 25(8):859-866. PubMed ID: 31347980
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs.
Giuliani J; Bonetti A
Clin Breast Cancer; 2019 Aug; 19(4):e519-e521. PubMed ID: 30858036
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
[TBL] [Abstract][Full Text] [Related]
12. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
[TBL] [Abstract][Full Text] [Related]
13. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA
Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
[TBL] [Abstract][Full Text] [Related]
14. Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.
Rugo HS; Haltner A; Zhan L; Tran A; Bananis E; Hooper B; Mitra D; Cameron C
J Comp Eff Res; 2021 Apr; 10(6):457-467. PubMed ID: 33626934
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
Cameron D; Kumar Sharma V; Biswas C; Clarke C; Chandiwana D; Pathak P
J Med Econ; 2023; 26(1):357-365. PubMed ID: 36797664
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer.
Mamiya H; Tahara RK; Tolaney SM; Choudhry NK; Najafzadeh M
Ann Oncol; 2017 Aug; 28(8):1825-1831. PubMed ID: 28472324
[TBL] [Abstract][Full Text] [Related]
18. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
Raphael J; Helou J; Pritchard KI; Naimark DM
Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
[TBL] [Abstract][Full Text] [Related]
19. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
